^
+ Follow CANCER FACTS AND ESTIMATES Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1515058
                    [Title] => Rx: Quality of life for lung cancer patients
                    [Summary] => 

Recently, we were invited to a symposium on the advances in the treatment and management of lung cancer.

[DatePublished] => 2015-10-26 10:00:00 [ColumnID] => 133914 [Focus] => 0 [AuthorID] => 1096607 [AuthorName] => Ching M. Alano [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [1] => Array ( [ArticleID] => 733958 [Title] => Roche lung cancer drug receives FDA approval [Summary] =>

Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.

[DatePublished] => 2011-10-06 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
CANCER FACTS AND ESTIMATES
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1515058
                    [Title] => Rx: Quality of life for lung cancer patients
                    [Summary] => 

Recently, we were invited to a symposium on the advances in the treatment and management of lung cancer.

[DatePublished] => 2015-10-26 10:00:00 [ColumnID] => 133914 [Focus] => 0 [AuthorID] => 1096607 [AuthorName] => Ching M. Alano [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [1] => Array ( [ArticleID] => 733958 [Title] => Roche lung cancer drug receives FDA approval [Summary] =>

Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.

[DatePublished] => 2011-10-06 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with